

In the claims:

Please amend the claims as follows:

1-7. **(Canceled)**

8. **(Previously presented)** A preparation comprising at least 70% biologically active receptor-immunoglobulin fusion protein (receptor-Ig-fusion protein), obtained by culturing a mammalian host cell transformed with DNA encoding the receptor-Ig fusion protein in a culture system having a temperature of about 27° C to about 35° C, wherein the receptor-Ig fusion protein comprises a member of the TNF family of receptors.

9. **(Canceled)**

10. **(Previously presented)** The preparation of claim 8, wherein the receptor-Ig-fusion protein comprises lymphotoxin-β receptor (LT-β-R)-Ig fusion protein.

11. **(Previously presented)** The preparation of claim 8, wherein the receptor-Ig-fusion protein comprises herpes virus entry mediator (HVEM)-Ig-fusion protein.

12-15. **(Canceled)**

16. **(Previously presented)** A pharmaceutical preparation obtained by
(a) culturing a host cell transformed with DNA encoding a lymphotoxin-β receptor (LT-β-R)-Ig-fusion protein in a culture system having a temperature of about 27° C to about 32 ° C, thereby expressing biologically active LT-β-R-Ig-fusion proteins;
(b) recovering biologically active LT-β-R-Ig-fusion proteins from said culture system; and
(c) combining the biologically active LT-β-R-Ig-fusion proteins of step (b) with a pharmaceutically acceptable carrier.

17-25. **(Canceled)**

26. **(Previously presented)** A preparation comprising a biologically active receptor-Ig-fusion protein obtained by culturing yeast transformed with DNA encoding the receptor-Ig-fusion protein in a culture system having a temperature of about 10° C to about 25° C, wherein the receptor-Ig fusion protein comprises a member of the TNF family of receptors.

27. **(Cancel)**

28. **(Previously presented)** The preparation of claim 26, wherein the receptor-Ig-fusion protein comprises LT-β-R-Ig-fusion protein.

29. **(Previously presented)** The preparation of claim 26, wherein the receptor-Ig-fusion protein comprises HVEM-Ig-fusion protein.

30-36. **(Canceled)**

37. **(Currently amended)** A preparation comprising at least 70% biologically active HVEM-Ig-fusion protein proteins obtained by culturing a mammalian host cell transformed with DNA encoding the HVEM-Ig-fusion protein in a culture system having a temperature of about 27° C to about 35 ° C.

38. **(Previously presented)** The preparation of claim 37, wherein the culture system has a temperature of about 27° C to about 32 ° C.

39. **(Previously presented)** The preparation of any one of claims 8, 10, and 11, wherein the culture system has a temperature of about 27° C to about 32 ° C.

40. **(Previously presented)** The preparation of claim 8 or 10, wherein the host cell is a Chinese hamster ovary (CHO) cell or a COS cell.

41. **(Previously presented)** The preparation of claim 16, wherein the host cell is a CHO cell or a COS cell.

42. **(Previously presented)** The preparation of claim 8 or 10, wherein the preparation is a cell culture supernatant.

43. **(New)** The preparation of claim 8, wherein the preparation comprises at least 83% biologically active receptor-Ig-fusion protein.

44. **(New)** A preparation comprising at least 70% biologically active LT- β -R-Ig-fusion protein obtained by culturing a mammalian host cell transformed with DNA encoding the LT- β -R-Ig-fusion protein in a culture system having a temperature of about 27° C to about 35 ° C.

45. **(New)** The preparation of claim 44, wherein the culture system has a temperature of about 27° C to about 32 ° C.

46. **(New)** The preparation of claim 44, wherein the host cell is a CHO cell or a COS cell.

47. **(New)** The preparation of claim 44, wherein the preparation is a cell culture supernatant.

48. **(New)** The preparation of claim 44, wherein the preparation comprises at least 83% biologically active LT- β -R-Ig-fusion protein.